The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
SOHO 2023 | The evolving role of CAR-T therapy in CLL
Nitin Jain, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses the evolving role of CAR-T therapy in the treatment of chronic lymphocytic leukemia (CLL), which has lagged behind other B-cell malignancies. Dr Jain describes the renewed interest in CAR-T for patients with CLL who relapse after BCL2 and BTK inhibitors, and highlights a trial investigating lisocabtagene maraleucel (liso-cel). This interview took place at the Eleventh Annual Meeting of the Society of Hematologic Oncology (SOHO 2023) held in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
